Liver cancer in 2013: Mutational landscape of HCC - The end of the beginning

Nature Reviews Clinical Oncology

Volumn 11, Issue 2, 2014, Pages 73-74

  Villanueva, Augusto ^a   Llovet, Josep M ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; TIME FACTORS;

EID: 84895901513     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.243     Document Type: Review

References (10)

1. Lonzano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
2. Cleary, S. P. et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology http://dx.doi.org/10.1002/hep.26540.
3. Guichard, C. et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694-698 (2012).
4. Kan, Z. et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 23, 1422-1433 (2013).
5. Chiang, D. Y. et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 68, 6779-6788 (2008).
6. Nault, J. C. et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. N at. Commun. http://dx.doi.org/10.1038/ncomms3218 (2013).
7. Johnson, P. J. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the r andomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517-3524 (2013).
8. Llovet, J. M. et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for who m sorafenib failed: Results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 31, 3509-3516 (2013).
9. Hoshida, Y. et al. Prognostic gene expression signature for patients with hepatitis C-related early stage cirrhosis. Gastroenterology 144, 1024-1030 (2013).
10. He, G. et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155, 384-396 (2013).